The GRS for higher TSH specific to the platelet activation, signalling and aggregation pathway (Reactome, including novel genes GNG7, ANXA5, PRKCZ) was associated with increased hypothyroidism risk, reduced nontoxic nodular goitre and simple goitre risk, raised urate, creatinine and reduced eGFR, reduced sex hormone binding globulin and testosterone, increased waist-hip-ratio, handgrip strength and whole body fat-free mass, osteochondropathies, increased triglyceride levels, and with lipid composition traits (Fig. 3b). This evidence concerns the gene ANXA5 and bone disorder.